Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

This Phase I study evaluates (2R,6R)-hydroxynorketamine hydrochloride in healthy adult volunteers using a slow 40-minute intravenous infusion across single ascending dose (SAD) cohorts, multiple ascending dose (MAD) cohorts, and a CSF capture cohort. Primary objectives are safety, tolerability, and pharmacokinetics including plasma and CSF sampling.

Safety assessments include AEs/SAEs, vitals, ECGs, clinical labs, ophthalmologic exams, C-SSRS, POMS, CADSS and MOAA/S. Pharmacodynamic measures include qEEG and serial PK sampling at multiple timepoints.

Study design incorporates sentinel dosing, placebo controls in each cohort, and predefined halting rules for dose escalation; MAD dosing occurs over four administrations with intensive safety monitoring.

Participants

Ages

18 – 65

Sexes

Male & Female

BMI

18 - 35

Psychosis History

Inclusion Criteria

Inclusion Criteria:
1. Be a healthy male or female between 18 and 65 years of age (inclusive).
2. Voluntarily consents to participate in the study and provides written informed consent before the start of any study-specific procedures.
3. Be willing and able to remain in the study unit for the entire duration of the confinement period and return for outpatient visits.
4. Agree to comply with prohibitions and restrictions (section 8.5).
5. Females must have a negative serum β-human chorionic gonadotropin (hCG) pregnancy test at screening and a negative urine pregnancy test on Day -1 prior to study initiation.
6. Females must be of nonchildbearing potential or agree to use appropriate birth control, as defined in section 8.4 Contraception Requirements.
7. Males must be surgically sterile for at least 90 days before screening or agree to use a condom with spermicide when sexually active with a female partner who is not using an acceptable form of birth control during the study and for 90 days after study administration. Males must also agree to not donate sperm starting at enrollment and for 90 days after last study drug administration.
8. BMI (weight [kg]/[m2]) between 18 and 35 kg/m2 (inclusive) and weighs between 50 and 120 kg (110 - 264 pounds), inclusive.
9. Blood pressure (after Subject is in a supine position for approximately 5 minutes) between 90 and 145 mmHg systolic (inclusive) and no higher than 90 mmHg diastolic at Screening and Day -1.
10. A 12-lead ECG with no clinically significant abnormality as judged by the Investigator and QTc interval ≤ 450 milliseconds at Screening and Day -1.
11. Resting pulse rate between 45 and 100 beats per minute at Screening and Day -1.
12. Clinical laboratory findings and VS within normal range, or if outside of the normal ranges, deemed not clinically significant in the opinion of the Investigator.
13. Agree to comply with the rules regarding consumption of alcohol, caffeinated beverages, and tobacco/nicotine products during the study.

Exclusion Criteria

Exclusion Criteria:
1. History or presence of clinically significant medical illness including (but not limited to) hepatic, cardiovascular, pulmonary, renal, hematologic, endocrine, gastrointestinal, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease that in the opinion of the Investigator would endanger the safety of the Subject or the validity of the study results.
2. Clinically significant acute illness in the 2 weeks prior to dosing.
3. Previous or current participation in any clinical study with an investigational drug, device, or biologic within 30 days or five half-lives of the investigational product to dosing.
4. Preplanned surgery or procedures that would interfere with the conduct of the study.
5. History of severe drug or excipient allergy, or hypersensitivity to be judged at the discretion of the Investigator.
6. Donation or loss of greater than 0.5 L of blood within 90 days before screening or study start. Donation of platelets within 40 days before screening or study start. Donation of plasma within 14 days before screening or study start. Receipt of blood products within 60 days before screening or study start.
7. Recent history (2 years) of alcohol or drug abuse at the discretion of the Investigator or a positive screen for alcohol or drugs of abuse (including marijuana) at screening and upon check-in.
8. Testing positive for hepatitis B, hepatitis C, or HIV, or a history of any of these diseases. Subjects whose results are compatible with prior immunization may be included at the discretion of the Investigator.
9. History of unexplained loss of consciousness, epilepsy, or other seizure disorders, or cerebrovascular disease.
10. Malignancy within 5 years of screening visit (except basal cell or squamous cell skin carcinoma).
11. Inability to adhere to the study unit diet.
12. Use of any prescription or nonprescription medication (including vitamins, herbal preparations, and nutritional supplements) within the 14 days prior to dosing except for common analgesics (acetaminophen, ibuprofen), hormonal contraceptives or hormonal replacement therapy or nonsedating antihistamines. Topical medications may be allowed at the discretion of the Investigator.
13. History or current diagnosis of mental illness including (but not limited to) psychotic disorder, bipolar disorder, schizophrenia, borderline personality disorder, and antisocial personality disorder, generalized anxiety disorder, obsessive compulsive disorder, posttraumatic stress disorder, and eating disorders.

Company

Product

Legal

Detailed Description

Study Protocol

Preparation

Locations

Related Publications

Arketamine as adjunctive therapy for treatment-resistant depression: A placebo-controlled pilot study

Dosing

Integration

Study Arms & Interventions

SAD cohorts

Interventions

MAD cohorts

Interventions

CSF cohort

Interventions

Placebo

Interventions

Participants

Inclusion Criteria

Exclusion Criteria

Study Details

Study Team

Sponsors & Collaborators

A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers